1 Recommendations

1 Recommendations

1.1 Evidence on the safety of selective internal radiation therapy (SIRT) for unresectable colorectal metastases in the liver shows there can be serious complications, but these are well recognised and infrequent.

  • In people who cannot tolerate chemotherapy or have liver metastases that are refractory to chemotherapy, there is evidence of efficacy but this is limited, particularly for important outcomes such as quality of life. Therefore, in these people, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

  • In people who can have chemotherapy, evidence on overall survival and quality of life is inadequate in quality. Therefore, in these people, this procedure should only be used in the context of research.

1.2 Clinicians wishing to do SIRT for unresectable colorectal metastases in the liver, in people who cannot have chemotherapy or have liver metastases that are refractory to chemotherapy, should:

  • Inform the clinical governance leads in their NHS trusts.

  • Give patients clear written information to support shared decision making, including NICE's information for the public.

  • Ensure that patients understand the procedure's safety and efficacy, as well as any uncertainties about these.

  • Audit and review clinical outcomes of all patients having the procedure. Clinicians should enter details for all patients having SIRT for unresectable colorectal metastases in the liver onto a suitable register.

1.3 Patient selection should be done by a specialist hepatobiliary cancer multidisciplinary team that can offer the full range of treatment options for this condition.

1.4 This procedure should only be done by clinicians with specific training in SIRT including techniques to minimise the risk of damage to surrounding tissue.

1.5 Further research should report details of patient selection, whether the primary colorectal tumour arose in the left or right side of the colon, extrahepatic disease, and tumour‑to‑liver volume. Outcomes should include survival and quality of life.

1.6 NICE may update the guidance on publication of further evidence.

  • National Institute for Health and Care Excellence (NICE)